$VTAK

After-hours gains Monday lifted small-cap Catheter Precision (VTAK), Infleqtion (INFQ), and Oriental Rise Holdings (ORIS). VTAK rose nearly 61% after Flyte partnership with GSE Worldwide and Emiliano Grillo plus new heart-failure patents. INFQ jumped over 12% after Trump quantum executive orders and its Quantum Space Initiative. ORIS gained about 22% after a one-for-four reverse split took effect.

Catheter Precision, Inc. (VTAK) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. EX-3.1 2 ex_993841.htm EXHIBIT 3.1 ex_993841.htm Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C-4 CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1. I am the Chief Financia

Flyte (NYSE American: VTAK) announced a strategic partnership with 319 Golf Society, naming Flyte the Society’s exclusive private aviation partner. The company says 319 members get $1,000 toward their first Flyte trip plus merchandise and event access. Flyte will use its Cirrus Vision Jet fleet operated by FAA-certified Ponderosa Air, targeting short-haul travel between private clubs and resorts.

Investorideas.com reports aviation-stock momentum tied to Fly Flyte, Inc., a Regional Air Mobility subsidiary of Catheter Precision, Inc. (VTAK). Flyte said it will partner with Blade Urban Air Mobility to feature its Cirrus Vision Jet fleet on Blade’s platform. The article also notes Blade’s integration into Uber and mentions JOBY and ACHR developments.

Catheter Precision’s (NYSE American: VTAK) Flyte unit said it partnered with Blade Urban Air Mobility to feature Flyte’s Cirrus Vision Jet fleet and charter offerings on Blade’s platform. The non-exclusive deal aims to expand distribution, increase aircraft utilization, and drive brand awareness and booking opportunities for regional travel.

Catheter Precision, Inc. (VTAK) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. EX-3.1 2 ex_988166.htm EXHIBIT 3.1 SERIES C-3 DESIGNATION ex_988166.htm Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C-3 CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1.

Catheter Precision, Inc. (VTAK) reported preliminary unaudited Q2 2026 revenues of $1.037 million for the quarter ended June 30, 2026. The MedTech segment rose 27% vs Q2 2025, while the Flyte Vision Jet segment increased 61% sequentially over Q1 2026 to $767,000. The company also cited over $400,000 in revenue for the first two weeks of July 2026.

Catheter Precision Inc. (VTAK) shares rose 19.36% to $0.67 after hours Tuesday after a 13.90% intraday drop to $0.56. Benzinga Pro data showed volume of 23.68M shares. The move followed a Jul. 10 SEC prospectus registering resale of 68.06M shares from preferred conversions and warrant exercises, warning of potential dilution.

Catheter Precision (NYSE:VTAK) shares fell about 26% on Friday as traders unwound earlier headline-driven gains. Earlier this week, the company said Flyte would equip its Cirrus Vision Jet fleet with LifeVac airway-clearance devices, and it also announced two patents covering its VIVO mapping platform and Cardionomix heart failure portfolio. The stock was down to about $0.83.

Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), said its enhanced direct-to-consumer booking platform (flyflyte.com) launched and drove early growth in 1H 2026. It added 1,000+ users, facilitated 118 flights, and generated $1.0M+ revenue. The platform supports direct bookings and broker or advisor partners, using AI-enabled pricing and marketing.